Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.74 USD
+1.37 (2.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $63.73 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Illumina (ILMN) Rides on New Products, Low Margin a Concern
by Zacks Equity Research
Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.
Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
by Zacks Equity Research
Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.
Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
by Zacks Equity Research
Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.
Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2
by Zacks Equity Research
Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.
ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track
by Zacks Equity Research
ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.
New Strong Buy Stocks for August 1st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.
Edwards Lifesciences (EW) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Edwards Lifesciences (EW) Q2 Earnings: A Surprise in Store?
by Zacks Equity Research
Edwards Lifesciences (EW) will likely ride high in Q2 earnings banking on continued growth in its highly advanced Transcatheter Heart Valve space.
Haemonetics Plasma Arm Advances, Blood Center Sluggish
by Zacks Equity Research
On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).
BioTelemetry (BEAT) Acquires LifeWatch for $280 Million
by Zacks Equity Research
BioTelemetry Inc. (BEAT) enhances its position in the wireless medicine space, enlarges product profile and customer base in cardiac monitoring and diagnostic services with LifeWatch buyout.
Avantor to Acquire VWR, Consolidation Promises Global Gains
by Zacks Equity Research
On Jul 14, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).
DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
by Zacks Equity Research
DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.
Zimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
by Zacks Equity Research
Indiana-based Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the global musculoskeletal space, recently announced second-quarter 2017 preliminary results.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
McKesson (MCK) Poised on Improving Generic and Brand Market
by Zacks Equity Research
On Jul 12, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK).
LabCorp Diagnostics Strong on Novant Health Deal Extension
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH), also referred to as LabCorp, has decided to extend its Technical Services Agreement with Novant Health which was originated in 2012.
CVS Health's MinuteClinic Joins EOHN for Workplace Healthcare
by Zacks Equity Research
MinuteClinic, the retail medical clinic of CVS Health Corporation (CVS), announced a tie-up with the Alere eScreen Occupational Health Network.
Express Scripts Rides High on Increased Generic Utilization
by Zacks Equity Research
On Jul 10, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).
PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation
by Zacks Equity Research
PAREXEL International Corporation (PRXL) was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.
Neogen Introduces Test for Listeria in Environmental Samples
by Zacks Equity Research
Neogen Corporation (NEOG) recently developed Listeria Right Now test system.
MedTech Industry Outlook - July 2017
by Zacks Equity Research
The overall expectation is that President Trump's legislative change for MedTech will result in lower taxes and regulation for the industry as a whole.
Top Stock Picks for the Week of May 29th
by Panel Of Zacks Experts
A Value and Medical Growth Play to Consider.
Why Is Edwards Lifesciences (EW) Up 4.5% Since the Last Earnings Report?
by Zacks Equity Research
EW reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.